Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Autor: Sabin Goktas Aydin, Burcin Cakan Demirel, Ahmet Bilici, Atakan Topcu, Musa Barış Aykan, Seda Kahraman, Ilgın Akbıyık, Muhammed Mustafa Atci, Omer Fatih Olmez, Arzu Yaren, Mehmet Ali Nahit Sendur, Caglayan Geredeli, Mesut Seker, Yuksel Urun, Nuri Karadurmus, Ahmet Aydin
Přispěvatelé: TOPÇU, ATAKAN, ŞEKER, MESUT
Rok vydání: 2022
Předmět:
cancer patient
leukocyte count
vomiting
Neutrophils
retrospective study
Sağlık Bilimleri
Fundamental Medical Sciences
Clinical Medicine (MED)
fluorouracil
TIP
GENEL & DAHİLİ
advanced cancer
Klinik Tıp (MED)
Lymphocytes
Prospective Studies
cancer survival
kidney function
MEDICINE
GENERAL & INTERNAL
Second-Line Chemotherapy
antineoplastic agent
irinotecan
progression free survival
Klinik Tıp
second-line chemotherapy
capecitabine
adult
gemcitabine
neutrophil
General Medicine
biliary tract tumor
biological marker
nausea
Prognosis
SII
Tıp
aged
female
Biliary Tract Neoplasms
liver function
cancer therapy
Medicine
Best Supportive Care
prospective study
survival rate
side effect
folinic acid
overall survival
Temel Tıp Bilimleri
Biliary Tract Cancer
lymphocyte
Genel Tıp
Article
NLR
best supportive care
male
Health Sciences
follow up
Humans
controlled study
human
Retrospective Studies
Inflammation
hemoglobin blood level
ECOG Performance Status
median survival time
neutrophil count
oxaliplatin
hemoglobin
CLINICAL MEDICINE
major clinical study
human tissue
infection
neutrophil lymphocyte ratio
Biliary tract cancer
regorafenib
fatigue
pathology
Biomarkers
Zdroj: Current medical research and opinion. 38(10)
ISSN: 1473-4877
Popis: Objectives: Advanced-stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study, we aimed to investigate the role of systemic inflammatory parameters (SIP) and other possible independent factors that may affect survival and treatment approaches and to determine the benefit of later-line treatments in these patients. Methods: A total of 284 patients, initially diagnosed with advanced stage or progressed after curative treatment of BTC, from different oncology centers in Turkey were included in this retrospective study. The prognostic significance of clinicopathological factors, SIPs and treatment options was analyzed. Results: At a median follow-up of 13 months, the median progression-free survival (PFS) was 6.1 months (95% CI:5.51–6.82), and the median overall survival (OS) time was 16.8 months (95% CI: 13.9–19.6). Treatment choice (p
Databáze: OpenAIRE
Externí odkaz: